BioSig Commences Clinical Trial Enrollment for PURE EP System

Westport, CT, Nov. 21, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company commenced its first clinical trial for its PURE EP™ System. Texas Cardiac Arrhythmia Research Foundation (TCARF) in Austin, Texas, is the…